Related Experiment Video
Updated: Jul 17, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Steroid treatment for severe acute cryptogenic hepatitis
A Potthoff1, K Deterding, C Trautwein
1Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany.
Steroid treatment effectively managed severe acute cryptogenic hepatitis in a small study. This response suggests that autoimmune factors may underlie some cases of this liver condition.
Area of Science:
- Hepatology
- Immunology
- Internal Medicine
Background:
- Acute cryptogenic hepatitis can be self-limiting or indicate chronic liver disease.
- The etiology of acute cryptogenic hepatitis remains challenging to determine, often lacking specific diagnostic markers.
Observation:
- A retrospective analysis of four patients with acute cryptogenic hepatitis was conducted.
- Patients presented with elevated ALT and bilirubin, negative viral/autoimmune markers, and minimal histopathological findings suggestive of autoimmune hepatitis.
- Exclusion criteria included alcohol use, hepatotoxic drug intake, metabolic liver disease, and normal gamma globulin levels.
Findings:
- Patients received prednisolone for persistently high aminotransferases and impaired liver function.
- All patients showed a positive response to steroids, with normalized liver function and decreased aminotransferases.
- One patient required azathioprine due to aminotransferase rebound during steroid tapering.
Implications:
- Steroids should be considered for treating severe acute cryptogenic hepatitis.
- A positive response to steroid therapy may indicate an autoimmune basis for the disease.
- Further research is warranted to confirm the role of immunosuppression in managing this condition.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Hepatitis
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Chronic Pancreatitis II: Collaborative Care
Assessment:
Viral Hepatitis I: Introduction
Inhibitors of Viral Protein Synthesis
